Obseva Logo highresolution.jpg
ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids
September 15, 2021 01:00 ET | ObsEva SA
-If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids- -NDA submission includes positive data...
Obseva Logo highresolution.jpg
ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 01:00 ET | ObsEva SA
GENEVA, Switzerland September 7, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today...
Obseva Logo highresolution.jpg
ObsEva Announces Second Quarter 2021 Financial Results and Business Update
August 05, 2021 01:00 ET | ObsEva SA
-Linzagolix (Yselty®) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing approval recommendation anticipated in Q4:21- -Linzagolix for endometriosis:...
Obseva Logo highresolution.jpg
ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Live Birth Outcomes Following IVF
August 04, 2021 01:00 ET | ObsEva SA
- A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patients Across Three Randomized, Placebo-Controlled Clinical Trials Published in the Journal of Human Reproduction- -A...
Obseva Logo highresolution.jpg
ObsEva to Present at Upcoming Investor Conferences
August 03, 2021 01:00 ET | ObsEva SA
GENEVA, Switzerland August 3, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today...
Obseva
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor
July 27, 2021 01:00 ET | ObsEva SA
Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation) i; agent is being studied in an area of significant unmet need   Ad hoc...
Obseva Logo4 (00000002).jpg
ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting
July 02, 2021 01:00 ET | ObsEva SA
-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and mini symposia–   GENEVA, Switzerland and BOSTON – July 2,...
Obseva Logo4 (00000002).jpg
ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting
June 30, 2021 01:00 ET | ObsEva SA
-Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for uterine contractility of IVF patients prior to embryo...
Obseva Logo4 (00000002).jpg
ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting
June 24, 2021 01:00 ET | ObsEva SA
  - Data from Phase 3 study of Yselty® (linzagolix) for the treatment of uterine fibroids to be discussed in an oral presentation; Top-line data from pilot study of Yselty for the treatment of...
Obseva Logo4 (00000002).jpg
ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021
June 10, 2021 01:00 ET | ObsEva SA
  -PROLONG data demonstrating ebopiprant was well tolerated and showed early evidence of efficacy selected for presentation- - Phase 2b/3 adaptive dose-ranging study planned to initiate in Q4:21- ...